The European Medicines Agency (EMA) and the European Commission on Friday launched an information guide on biosimilar medicines for the better understanding of these medicines.
The guide was aimed to offer scientific and regulatory reference to healthcare professionals about the use of biosimilars.
Biosimilars are medicines that are similar to authorized biological medicines in all essential aspects. EMA and the Commission worked with scientific experts from the EU to address questions in this area from healthcare professionals.
The EU approved the first biosimilar medicine in 2006. Since then, the agency's Committee for Medicinal Products for Human Use has recommended 28 biosimilars for use in the bloc, said the EMA.
Evidence showed that biosimilars approved in the bloc are safe and effective as other biological medicines, it said.
